文献速递心脑血管急症

长期秋水仙碱预防非心源性栓塞性卒中血管复发事件(CONVINCE):一项随机对照试验

Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
PubMed 文献 · Lancet · 2024-06-07
一句话结论非严重非心源性栓塞性卒中或高危TIA后长期秋水仙碱0.5 mg/d未显著降低主要复合终点(HR 0.84,95%CI 0.68-1.05,p=0.12),但为抗炎治疗进一步随机试验提供依据。

CONVINCE为随机、平行组、开放标签、盲法终点评估试验,比较长期秋水仙碱(0.5 mg口服每日)联合指南常规治疗与单纯常规治疗,纳入非严重、非心源性栓塞性缺血性卒中或高危TIA住院患者。共3154例随机,3144例进入意向性治疗分析(秋水仙碱组1569例,单纯常规组1575例)。主要终点(首次致死或非致死复发缺血性卒中、心肌梗死、心脏骤停或因不稳定型心绞痛住院的复合终点)在秋水仙碱组153例(9.8%)vs 单纯常规组185例(11.7%),发生率3.32 vs 3.92/100人年,HR 0.84(95%CI 0.68-1.05),p=0.12,未达预设显著性界值0.048。秋水仙碱组28天及1、2、3年CRP较低(各时间点p<0.05),严重不良事件两组相似。

要点

  • 主要复合终点秋水仙碱组153/1569(9.8%)vs 单纯常规组185/1575(11.7%),发生率3.32 vs 3.92/100人年,HR 0.84(95%CI 0.68-1.05),p=0.12,未达显著。
  • 试验因COVID-19疫情相关预算限制提前终止,未达到预期367个结局数。
  • 秋水仙碱0.5 mg口服每日组在28天及1、2、3年CRP均低于单纯常规组(各时间点p<0.05)。
  • 两组严重不良事件发生率相似。
  • 预设显著性界值为p=0.048,以校正数据监测委员会进行的两次预设中期分析。

适用人群与场景

  • 住院的非严重、非心源性栓塞性缺血性卒中或高危短暂性脑缺血发作患者。

诊断标准与关键阈值

  • 主要终点为首次致死或非致死复发缺血性卒中、心肌梗死、心脏骤停或因不稳定型心绞痛住院(定义为入住住院单元或急诊就诊导致至少24小时停留[若入院或出院时间不可得,则以日历日期变更计])的复合终点。
  • 预设显著性界值为p=0.048,以校正数据监测委员会进行的两次预设中期分析。

处置流程与药物剂量

  • 秋水仙碱0.5 mg口服每日,联合指南常规治疗,与单纯常规治疗比较。

研究设计与关键结果

  • 随机、平行组、开放标签、盲法终点评估试验,2016年12月19日至2022年11月21日随机3154例,末次随访2024年1月31日;10例撤回数据知情同意,3144例进入意向性治疗分析:秋水仙碱联合常规治疗组1569例,单纯常规治疗组1575例。
  • 主要终点发生于338例:秋水仙碱联合常规治疗组153/1569(9.8%)vs 单纯常规治疗组185/1575(11.7%),发生率3.32 vs 3.92/100人年,HR 0.84(95%CI 0.68-1.05),p=0.12。
  • 试验因COVID-19疫情相关预算限制,在达到预期367个结局数前提前终止。
  • 基线CRP两组无差异,秋水仙碱组28天及1、2、3年CRP较低(各时间点p<0.05)。
  • 严重不良事件发生率两组相似。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 局限:试验因COVID-19疫情相关预算限制提前终止,未达到预期367个结局数;主要分析未达统计学显著。

对床旁实践的改变

  • 作者认为,尽管意向性治疗主要分析未观察到统计学显著获益,这些发现为抗炎治疗在进一步随机试验中的合理性提供了新证据。

指南或共识出处

  • CONVINCE试验,注册号ClinicalTrials.gov NCT02898610。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.

METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed.

FINDINGS: 3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68-1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups.

INTERPRETATION: Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials.

FUNDING: Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kelly P, Lemmens R, Weimar C, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. 2024. PMID: 38857611. doi:10.1016/S0140-6736(24)00968-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。